Sodium glucose linked transporter 2 (SGLT-2) inhibitors should be considered as a therapeutic alternative, but they also carry an increased risk of diabetic ketoacidosis when used in combination with alcohol.34 Promising early studies suggest that prescribing Glucagon-Like Peptide 1 (GLP-1) agonists to patients with type-2 diabetes mellitus and AUD may lead to a reduction in alcohol consumption.35,36. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.